Combining a targeted drug, palbociclib with hormone therapy substantially extends survival for women with Advanced Breast Cancer, according to a major new study published in the latest issue of the New England Journal of Medicine. Women taking palbociclib together with hormone therapy lived seven months longer than those on hormone treatment alone – adding to previous data showing the combination could delay the disease’s progression. The drug’s benefit was stronger in women who had previously responded to hormone therapy – who lived 10 months longer with the combination treatment. The international PALOMA-3 clinical trial was led by researchers at The

The post Palbociclib Targets Advanced Breast cancer appeared first on The Hippocratic Post.